CSA Medical, Inc. Selected to Present at AdvaMed 2010: The MedTech Conference

CSA Medical is first to harness the power of extreme cold, liquid nitrogen (-196 C), therapeutic energy delivery inside the body. This unique technology (device, catheter and agent) allows delivery of therapeutic doses of a cryogen to destroy diseased tissue inside the body while preserving the stromal matrix. This cell death with scaffolding preservation is unique to liquid nitrogen spray cryotherapy. Financial highlights, product development and commercialization plans for CSA Medical's novel Spray Cryotherapy technology will be overviewed during the presentation.

"We are looking forward to a busy and exciting meeting as our schedule is full with strategic partner and investor meetings," said Steve Schaefer, the company's President and CFO. "CSA Medical addresses the expanding need for minimally invasive treatment options. Patients and physicians want clinically effective therapy with less pain and morbidity and quick recovery when possible. Patented, spray cryotherapy delivers on these needs as evidenced by the growing number of users and procedures performed."

AdvaMed is the national trade association for medical device, diagnostic and heath information system companies. These companies manufacture 90% of the health care technology produced annually in the United States and 50% globally. The annual MedTech conference will attract over 1,400 business leaders, entrepreneurs, policy-makers, media, financiers, and other industry stakeholders from around the world including 500+ CEOs, Presidents and C-level executives.

CSA Medical, Inc. develops and manufactures a proprietary therapeutic interventional platform, the CryoSpray Ablation System. The CSA System utilizes a patented spray cryogenic technology that allows a physician to freeze and destroy a wide range of unwanted tissues via an endoscope.

For more information, please contact Richard Hughen at rhughen@csamedical.com or www.CSAmedical.com.

SOURCE CSA Medical, Inc.